Holen Sie sich die Stockscreener-App
62.95
1.58%
1.22
Schlusskurs vom Vortag:
$61.73
Offen:
$61.46
24-Stunden-Volumen:
988.88K
Relative Volume:
0.40
Marktkapitalisierung:
$7.84B
Einnahmen:
$692.26M
Nettoeinkommen (Verlust:
$-512.41M
KGV:
-14.85
EPS:
-4.24
Netto-Cashflow:
$-274.36M
1W Leistung:
-1.16%
1M Leistung:
+14.23%
6M Leistung:
+38.85%
1J Leistung:
+193.84%
1-Tages-Spanne:
$61.00
$63.77
1-Wochen-Bereich:
$61.00
$66.57
52-Wochen-Spanne:
$20.14
$68.00
Guardant Health Inc Stock (GH) Company Profile
Firmenname
Guardant Health Inc
Sektor
Branche
Telefon
855-698-8887
Adresse
3100 HANOVER STREET, PALO ALTO
Vergleichen Sie GH mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GH
Guardant Health Inc
|
62.90 | 7.70B | 692.26M | -512.41M | -274.36M | -4.24 |
|
TMO
Thermo Fisher Scientific Inc
|
526.04 | 198.09B | 43.21B | 6.58B | 6.17B | 17.28 |
|
DHR
Danaher Corp
|
206.36 | 146.89B | 24.01B | 3.41B | 4.86B | 4.7082 |
|
IDXX
Idexx Laboratories Inc
|
636.70 | 50.67B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
138.29 | 39.19B | 6.79B | 1.22B | 1.09B | 4.2644 |
|
IQV
Iqvia Holdings Inc
|
205.09 | 34.64B | 15.70B | 1.24B | 2.01B | 6.9036 |
Guardant Health Inc Stock (GH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-25 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-09-22 | Fortgesetzt | Wells Fargo | Overweight |
| 2025-04-10 | Eingeleitet | Mizuho | Outperform |
| 2025-01-23 | Eingeleitet | Barclays | Overweight |
| 2024-06-28 | Hochstufung | Guggenheim | Neutral → Buy |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-04-24 | Fortgesetzt | Craig Hallum | Buy |
| 2023-12-14 | Eingeleitet | Guggenheim | Neutral |
| 2023-12-13 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-11-13 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-09-28 | Eingeleitet | Bernstein | Outperform |
| 2023-09-27 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
| 2023-05-26 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-05-05 | Eingeleitet | UBS | Buy |
| 2023-03-09 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-01-05 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-11-01 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-10-19 | Eingeleitet | Craig Hallum | Buy |
| 2022-10-06 | Eingeleitet | Stephens | Overweight |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-06-03 | Eingeleitet | Piper Sandler | Overweight |
| 2022-04-28 | Fortgesetzt | BTIG Research | Buy |
| 2022-02-24 | Bestätigt | Canaccord Genuity | Buy |
| 2022-02-24 | Bestätigt | Citigroup | Buy |
| 2022-02-24 | Bestätigt | Cowen | Outperform |
| 2022-02-24 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-24 | Bestätigt | SVB Leerink | Outperform |
| 2022-02-24 | Bestätigt | Stifel | Buy |
| 2022-02-24 | Bestätigt | Wells Fargo | Overweight |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-06-15 | Eingeleitet | Raymond James | Mkt Perform |
| 2021-06-03 | Eingeleitet | Goldman | Buy |
| 2021-05-25 | Eingeleitet | Wells Fargo | Overweight |
| 2021-01-11 | Eingeleitet | Stifel | Buy |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-06-12 | Eingeleitet | BTIG Research | Buy |
| 2020-02-21 | Eingeleitet | Guggenheim | Buy |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-08-07 | Bestätigt | Canaccord Genuity | Buy |
| 2019-04-16 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-04-10 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-02-28 | Bestätigt | BofA/Merrill | Neutral |
| 2018-10-29 | Eingeleitet | BofA/Merrill | Neutral |
| 2018-10-29 | Eingeleitet | JP Morgan | Overweight |
| 2018-10-29 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Guardant Health Inc Aktie (GH) Neueste Nachrichten
Guardant Health: Hold Rating Ahead Of Q3 Results On Valuation And Execution Risk (GH) - Seeking Alpha
How to use Fibonacci retracement on Guardant Health Inc.Weekly Stock Analysis & Low Risk Growth Stock Ideas - newser.com
Can Guardant Health Inc. stock deliver consistent earnings growth2025 Price Momentum & Short-Term Swing Trade Alerts - newser.com
What institutional flow reveals about Guardant Health Inc.2025 Institutional Moves & Fast Momentum Stock Entry Tips - newser.com
Guardant Health, Inc. (GH) Stock Analysis: A Growth Powerhouse with a 6.81% Upside Potential - DirectorsTalk Interviews
What analysts say about Guardant Health Inc stockRisk-Reward Ratio Analysis & Best Stocks For Explosive Growth - earlytimes.in
Guardant Health, Inc. (NASDAQ:GH) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
How to track smart money flows in Guardant Health Inc.Weekly Gains Report & Daily Profit Focused Screening - newser.com
Using Ichimoku Cloud for Guardant Health Inc. technicals2025 Retail Activity & High Return Stock Watch Alerts - newser.com
Guardant Health to Report Third Quarter 2025 Financial Results on October 29, 2025 - Yahoo Finance
CustomerThink - CustomerThink
Quantitative breakdown of Guardant Health Inc. recent movePortfolio Update Report & Free Expert Verified Stock Movement Alerts - newser.com
Why Guardant Health Inc. (5GH) stock stays on top picksOptions Play & AI Powered Market Entry Strategies - newser.com
Pattern recognition hints at Guardant Health Inc. upsideTake Profit & Weekly High Conviction Trade Ideas - newser.com
Is Guardant Health Inc. building a consolidation base2025 Breakouts & Breakdowns & Trade Opportunity Analysis Reports - newser.com
Abel Hall LLC Invests $202,000 in Guardant Health, Inc. $GH - MarketBeat
Published on: 2025-10-09 03:21:22 - newser.com
Guardant Health's (GH) Sell (D-) Rating Reaffirmed at Weiss Ratings - MarketBeat
What drives Guardant Health Inc 5GH stock priceAnalyst Downgrades & Market Volatility Strategies - earlytimes.in
Evercore ISI Group Raises Price Target for Guardant Health (GH) to $68 | GH Stock News - GuruFocus
Evercore ISI Raises Guardant Health (NASDAQ:GH) Price Target to $68.00 - MarketBeat
Liquid Biopsy for Early Cancer Detection and Monitoring - GlobeNewswire
Liquid Biopsy for Early Cancer Detection and Monitoring Market Report 2025-2033, with Profiles of GRAIL, AnchorDx, Burning Rock Biotech, Genecast, Guardant Health, Elypta, Freenome, and Oncimmune - Yahoo Finance
Is Guardant Health Inc. (5GH) stock dividend growth reliableTrade Performance Summary & AI Forecast for Swing Trade Picks - newser.com
Visualizing Guardant Health Inc. stock with heatmapsCPI Data & Weekly Return Optimization Plans - newser.com
What momentum shifts mean for Guardant Health Inc.Quarterly Market Review & Precise Trade Entry Recommendations - newser.com
Using economic indicators to assess Guardant Health Inc. potentialJuly 2025 Drop Watch & Smart Allocation Stock Reports - newser.com
Guardant Health Inc Stock Analysis and ForecastMarket Liquidity Analysis & Rapid Capital Trading Plans - earlytimes.in
Shareholders in Guardant Health (NASDAQ:GH) Are in the Red If They Invested Three Years Ago - 富途牛牛
Guardant Health gets FDA nod for Guardant360 CDx as a companion diagnostic - MSN
How FDA Approval of Guardant360 CDx as Companion Diagnostic Could Impact Guardant Health (GH) Investors - Yahoo Finance
Is Quest Diagnostics' (DGX) Shield Partnership Transforming Its Role in Preventive Health Innovation? - Yahoo Finance
How to use a screener to detect Guardant Health Inc. breakoutsTrade Risk Report & Smart Money Movement Alerts - newser.com
Comparing Guardant Health Inc. in custom built stock radarsJuly 2025 WrapUp & Entry Point Strategy Guides - newser.com
Risk adjusted return profile for Guardant Health Inc. analyzedMarket Sentiment Report & Daily Momentum Trading Reports - newser.com
Barclays Raises Price Target for Guardant Health (GH) to $70.00 | GH Stock News - GuruFocus
4,782 Shares in Guardant Health, Inc. $GH Purchased by Trivium Point Advisory LLC - MarketBeat
GCC Liquid Biopsy Market Forecast and Company Analysis - GlobeNewswire
GCC Liquid Biopsy Market Forecast and Company Analysis Report 2025-2033 Featuring F. Hoffmann-La Roche, Bio-Rad, Thermo Fisher Scientific, Johnson & Johnson, Guardant Health, QIAGEN, Sysmex - Yahoo Finance
Sicart Associates LLC Increases Stock Holdings in Guardant Health, Inc. $GH - MarketBeat
Guardant Health, Inc. (GH) Unveils Shield V2, Boosts Early Cancer Detection Accuracy - Insider Monkey
What drives Guardant Health Inc stock priceEx-Dividend Date Alerts & Free Take Advantage Of Momentum - earlytimes.in
Stocks making big moves yesterday: Beyond Meat, The Trade Desk, Guardant Health, PayPal, and Tilray - The Globe and Mail
Guardant Health backs lung cancer screening advocacy campaign - Mugglehead Magazine
FDA approves Guardant360 CDx as companion diagnostic for breast cancer drug - Investing.com Nigeria
Guardant Health (GH) Secures FDA Approval for Diagnostic Test - GuruFocus
Guardant Health Hosts Investor Day in NYC - MSN
FDA Approves Guardant 360 CDx With Imlunestrant in ESR1+ Breast Cancer - Targeted Oncology
Finanzdaten der Guardant Health Inc-Aktie (GH)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.61%
1.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):